by Plus Therapeutics | Jun 25, 2025 | PBC
We are proud to announce that the U.S. Food and Drug Administration (FDA) has officially cleared Plus Therapeutics’ Investigational New Drug (IND) application for REYOBIQ™, a novel radiotherapeutic under development for the treatment of pediatric patients with...
by Plus Therapeutics | Jun 25, 2025 | PBC
FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial Plus Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has officially cleared its Investigational New Drug (IND) application for REYOBIQ™, a...
by Plus Therapeutics | Jun 16, 2025 | GBM
We are proud to highlight one of Plus Therapeutics’ leading Principal Investigators, Andrew Brenner, M.D., Ph.D., who recently appeared on KABB News to speak with Melissa Vega about the challenges and advancements in treating glioblastoma (GBM) — one of the most...
by Plus Therapeutics | Jun 16, 2025 | GBM
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle...
by Plus Therapeutics | Jun 12, 2025 | Uncategorized
At Plus Therapeutics, our mission is rooted in innovation, precision, and the pursuit of better outcomes for patients facing some of the most aggressive and difficult-to-treat cancers. In a recent interview with AlphaStreet, our President and CEO, Marc Hedrick, M.D.,...
Recent Comments